Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Diabetes

Free Subscription 13.01.2025 1 Am Heart J 1 Am J Hypertens 3 Ann Intern Med 3 Diabet Med 4 Diabetes 5 Diabetes Care 23 Diabetes Obes Metab 1 Diabetologia 2 Invest Ophthalmol Vis Sci 1 J Am Soc Nephrol 1 J Biol Chem 4 J Clin Endocrinol Metab 2 J Hypertens 2 JAMA 1 Med Care 2 Metabolism 9 PLoS One 1 Retina

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am Heart J

1. BLOOD AJ, Chang LS, Colling C, Stern G, et al
   Type 2 Diabetes Disease and Management Patterns Across a Large, Diverse Healthcare System: Issues and Opportunities for Guideline-Directed Therapies.
   Am Heart J. 2025 Jan 6:S0002-8703(25)00003-1. doi: 10.1016/j.ahj.2025.
   PubMed         Abstract available
   
   

   
   Am J Hypertens

2. NIKOLAIDOU B, Triantafyllou A, Anyfanti P, Gavriilaki E, et al
   Nighttime systolic blood pressure a major factor of retinal vascular caliber changes in patients with newly diagnosed type 2 diabetes mellitus.
   Am J Hypertens. 2025 Jan 10:hpaf004. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Ann Intern Med

3. 
   Annals Video Summary - Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.
   Ann Intern Med. 2025 Jan 7:e2403525VS. doi: 10.7326/ANNALS-24-03525.
   PubMed        
   
   
4. 
   Summary for Patients: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.
   Ann Intern Med. 2025 Jan 7. doi: 10.7326/ANNALS-24-01590.
   PubMed        
   
   
5. MOIZ A, Filion KB, Toutounchi H, Tsoukas MA, et al
   Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
   Ann Intern Med. 2025 Jan 7. doi: 10.7326/ANNALS-24-01590.
   PubMed         Abstract available
   
   

   
   Diabet Med

6. POUWER F, Barnard-Kelly K, Cleal BR, Cooke D, et al
   The missing piece: The clinical translation of precision diabetes medicine requires precision mental health care: A call to action from the international PsychoSocial Aspects of Diabetes (PSAD) Study Group.
   Diabet Med. 2025 Jan 11:e15514. doi: 10.1111/dme.15514.
   PubMed        
   
   
7. LIN Y, McCrimmon RJ, Pearson ER
   Exploring the potential role of C-peptide in type 2 diabetes management.
   Diabet Med. 2025 Jan 11:e15469. doi: 10.1111/dme.15469.
   PubMed         Abstract available
   
   
8. TERMANNSEN AD, Varming A, Bjerre N, Wodschow HZ, et al
   Protocol for a 1-year randomised, controlled, parallel group, open-label trial on the effects and feasibility of time-restricted eating in individuals with type 2 diabetes- The Restricted Eating Time in the Treatment of Type 2 Diabetes (RESET2) trial.
   Diabet Med. 2025 Jan 11:e15506. doi: 10.1111/dme.15506.
   PubMed         Abstract available
   
   

   
   Diabetes

9. LIN J, Zhang X, Ge W, Duan Y, et al
   Rnd3 Ameliorates Diabetic Cardiac Microvascular Injury via Facilitating Trim40-mediated Rock1 Ubiquitination.
   Diabetes. 2025 Jan 10:db240543. doi: 10.2337/db24-0543.
   PubMed         Abstract available
   
   
10. KWIATKOWSKA KM, Garagnani P, Bonafe M, Bacalini MG, et al
    High-resolution whole-genome DNA methylation revealed unique signatures of painful diabetic neuropathy.
    Diabetes. 2025 Jan 8:db240930. doi: 10.2337/db24-0930.
    PubMed         Abstract available
    
    
11. QUAST DR, Xie C, Bound MJ, Grivell J, et al
    Effects of metformin on postprandial blood pressure, heart rate, gastric emptying, GLP-1 and the prevalence of postprandial hypotension in type 2 diabetes - a double-blind, placebo-controlled crossover study.
    Diabetes. 2025 Jan 6:db240830. doi: 10.2337/db24-0830.
    PubMed         Abstract available
    
    
12. LU T, Manousaki D, Sun L, Paterson AD, et al
    Integrative proteogenomic analyses provide novel interpretations of type 1 diabetes risk loci through circulating proteins.
    Diabetes. 2025 Jan 6:db240380. doi: 10.2337/db24-0380.
    PubMed         Abstract available
    
    

    
    Diabetes Care

13. BEGZATI A, Godinez-Macias KP, Long T, Watrous JD, et al
    Plasma Lipid Metabolites, Clinical Glycemic Predictors, and Incident Type 2 Diabetes.
    Diabetes Care. 2025 Jan 6:dc242266. doi: 10.2337/dc24-2266.
    PubMed         Abstract available
    
    
14. KAZE AD, Bertoni AG, Fox ER, Hall ME, et al
    Diabetes, Subclinical Myocardial Injury or Stress and Risk of Heart Failure Subtypes: The Jackson Heart Study.
    Diabetes Care. 2025 Jan 6:dc240654. doi: 10.2337/dc24-0654.
    PubMed         Abstract available
    
    
15. PRADHAN R, Yin H, Lu S, Sebastiani G, et al
    Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes.
    Diabetes Care. 2025 Jan 8:dc241903. doi: 10.2337/dc24-1903.
    PubMed         Abstract available
    
    
16. OSMULSKI ME, Yu Y, Kuang A, Josefson JL, et al
    Subtypes of Gestational Diabetes Mellitus Are Differentially Associated With Newborn and Childhood Metabolic Outcomes.
    Diabetes Care. 2025 Jan 9:dc241735. doi: 10.2337/dc24-1735.
    PubMed         Abstract available
    
    
17. APPERLOO EM, Heerspink HJL, van der Aart AB, Rouw D, et al
    Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial.
    Diabetes Care. 2025 Jan 10:dc242244. doi: 10.2337/dc24-2244.
    PubMed        
    
    

    
    Diabetes Obes Metab

18. SON H, Sohn SH, Kim HA, Choe HJ, et al
    Real-time continuous glucose monitoring improves postoperative glucose control in people with type 2 diabetes mellitus undergoing coronary artery bypass grafting: A randomized clinical trial.
    Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16177.
    PubMed         Abstract available
    
    
19. VERMILLAC G, Lafont C, Godot C, Kerbourc'h S, et al
    Paediatric-to-adult transition in type 1 diabetes: A two-centre experience of a structured program, 2014 to 2022.
    Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16140.
    PubMed         Abstract available
    
    
20. CHEN M, Dou C, Ye C, Kong L, et al
    Socioeconomic and mental health inequalities in global burden of type 2 diabetes: Evidence from the Global Burden of Disease Study 2021.
    Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16173.
    PubMed         Abstract available
    
    
21. HOPKINS R, Young KG, Thomas NJ, Jones AG, et al
    Treatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population-based cohort study.
    Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16163.
    PubMed         Abstract available
    
    
22. SEUFERT J, Wiesner T, Pegelow K, Kenzler J, et al
    Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial.
    Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16161.
    PubMed         Abstract available
    
    
23. PODOBNIK J, Prentice KJ
    Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: Current clinical landscape and perspectives.
    Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16154.
    PubMed         Abstract available
    
    
24. COSENTINO F, Dagogo-Jack S, Frederich R, Cannon CP, et al
    Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.
    Diabetes Obes Metab. 2025;27:583-594.
    PubMed         Abstract available
    
    
25. HE Q, Cheng Z, Li Y, Xing X, et al
    A biweekly DPP-4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    Diabetes Obes Metab. 2025;27:965-975.
    PubMed         Abstract available
    
    
26. MORENO-LOPEZ M, Louvet I, Delalleau N, Acosta-Montalvo A, et al
    The role of the glucagon-FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition.
    Diabetes Obes Metab. 2025;27:885-898.
    PubMed         Abstract available
    
    
27. CERSOSIMO E, YueJuan Q, Baskoy G, Chavez A, et al
    Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients.
    Diabetes Obes Metab. 2025;27:944-952.
    PubMed         Abstract available
    
    
28. NEYER M, Vogel JB, Elsner P, Kuehrer H, et al
    Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysis.
    Diabetes Obes Metab. 2025;27:835-844.
    PubMed         Abstract available
    
    
29. USUI R, Hamamoto Y, Imura M, Omori Y, et al
    Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial.
    Diabetes Obes Metab. 2025;27:856-865.
    PubMed         Abstract available
    
    
30. ZHANG M, Lin C, Cai X, Jiao R, et al
    One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA.
    Diabetes Obes Metab. 2025;27:806-815.
    PubMed         Abstract available
    
    
31. SONG ZQ, Chen YQ, Xuan CH, Ni TT, et al
    Effect of smoking behaviour and related blood DNA methylation on visceral adipose tissues.
    Diabetes Obes Metab. 2025;27:619-628.
    PubMed         Abstract available
    
    
32. AO N, Du J, Jin S, Suo L, et al
    The cellular and molecular mechanisms mediating the protective effects of sodium-glucose linked transporter 2 inhibitors against metabolic dysfunction-associated fatty liver disease.
    Diabetes Obes Metab. 2025;27:457-467.
    PubMed         Abstract available
    
    
33. HAGGAG AZ, Xu J, Butcher L, Pagnussat S, et al
    Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.
    Diabetes Obes Metab. 2025;27:551-562.
    PubMed         Abstract available
    
    
34. ZHAO J, Sun Z, Li Z, Xu M, et al
    MicroRNA-mediated Ets1 repression in retinal endothelial cells: A novel anti-angiogenic mechanism in nonproliferative diabetic retinopathy.
    Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16182.
    PubMed         Abstract available
    
    
35. ALKHUZAM K, Li P, Abuloha S, Xue Q, et al
    Long-term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes.
    Diabetes Obes Metab. 2025 Jan 8. doi: 10.1111/dom.16168.
    PubMed         Abstract available
    
    
36. STICE E, Rohde P, Desjardins CD, Gee K, et al
    A preliminary randomized trial of a brief dissonance-based type 2 diabetes prevention programme for adults with pre-diabetes.
    Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16170.
    PubMed         Abstract available
    
    
37. HANSEN AL, Andersen MK, Engelhard LM, Brons C, et al
    Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes.
    Diabetes Obes Metab. 2025 Jan 8. doi: 10.1111/dom.16193.
    PubMed         Abstract available
    
    
38. TANG C, Hao J, Tao F, Feng Q, et al
    Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Jan 8. doi: 10.1111/dom.16192.
    PubMed         Abstract available
    
    
39. RUBINO DM, Pedersen SD, Connery L, Cao D, et al
    Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.
    Diabetes Obes Metab. 2025 Jan 9. doi: 10.1111/dom.16176.
    PubMed         Abstract available
    
    
40. FIORE V, Carbotta G, Barraco S, Falasca P, et al
    Real-world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide (SEMA-elderly).
    Diabetes Obes Metab. 2025 Jan 10. doi: 10.1111/dom.16174.
    PubMed         Abstract available
    
    

    
    Diabetologia

41. PACHECO LS, Tobias DK, Haslam DE, Drouin-Chartier JP, et al
    Sugar-sweetened or artificially sweetened beverage consumption, physical activity and risk of type 2 diabetes in US adults.
    Diabetologia. 2025 Jan 8. doi: 10.1007/s00125-024-06351.
    PubMed         Abstract available
    
    

    
    Invest Ophthalmol Vis Sci

42. PEI X, Ba M, Yang T, Xuan S, et al
    Leptin Receptor Deficiency-Associated Diabetes Disrupts Lacrimal Gland Circadian Rhythms and Contributes to Dry Eye Syndrome.
    Invest Ophthalmol Vis Sci. 2025;66:19.
    PubMed         Abstract available
    
    
43. OLIVEIRA S, Guimaraes P, Campos EJ, Fernandes R, et al
    Retinal OCT-Derived Texture Features as Potential Biomarkers for Early Diagnosis and Progression of Diabetic Retinopathy.
    Invest Ophthalmol Vis Sci. 2025;66:7.
    PubMed         Abstract available
    
    

    
    J Am Soc Nephrol

44. TANG M, Morieri ML, Kalim S, Doria A, et al
    Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
    J Am Soc Nephrol. 2025 Jan 7. doi: 10.1681/ASN.0000000620.
    PubMed        
    
    

    
    J Biol Chem

45. LI H, Lin L, Huang X, Lu Y, et al
    2-Hydroxylation is a chemical switch linking fatty acids to glucose-stimulated insulin secretion.
    J Biol Chem. 2024;300:107912.
    PubMed         Abstract available
    
    

    
    J Clin Endocrinol Metab

46. AMENDOLARA R, D'Onofrio L, Sessa RL, Di Giulio S, et al
    IFN-alpha neutralizing antibodies distinguish LADA from early-onset type 1 diabetes.
    J Clin Endocrinol Metab. 2025 Jan 6:dgaf001. doi: 10.1210.
    PubMed         Abstract available
    
    
47. DICKENS LT, Gonzalez MG
    Approach to the Patient using Diabetes Technology in Pregnancy.
    J Clin Endocrinol Metab. 2025 Jan 7:dgae914. doi: 10.1210.
    PubMed         Abstract available
    
    
48. HAAS AV, Koefoed AW, Celli J, Bonyhay I, et al
    Effect of Hypoglycemia on QT Interval in Individuals with and without Type 2 Diabetes: A Randomized Crossover Trial.
    J Clin Endocrinol Metab. 2025 Jan 9:dgae919. doi: 10.1210.
    PubMed         Abstract available
    
    
49. KIM S, Subramanian S
    Approach to Lipid Management in the Patient with Diabetes.
    J Clin Endocrinol Metab. 2025 Jan 11:dgaf018. doi: 10.1210.
    PubMed         Abstract available
    
    

    
    J Hypertens

50. TU Q, Hyun K, Lin S, Hafiz N, et al
    Impacts of hypertension and diabetes on the incidence of cardiovascular diseases and all-cause mortality: findings from the China Health and Retirement Longitudinal Study cohort.
    J Hypertens. 2024 Dec 12. doi: 10.1097/HJH.0000000000003946.
    PubMed         Abstract available
    
    
51. KIM JH, Oh S, Hong SJ, Yu CW, et al
    Minimum number of readings necessary for determining long-term visit-to-visit blood pressure variability to predict cardiovascular outcomes in people with diabetes.
    J Hypertens. 2024 Dec 18. doi: 10.1097/HJH.0000000000003954.
    PubMed         Abstract available
    
    

    
    JAMA

52. RADEMAKER D, de Wit L, Duijnhoven RG, Voormolen DN, et al
    Oral Glucose-Lowering Agents vs Insulin for Gestational Diabetes: A Randomized Clinical Trial.
    JAMA. 2025 Jan 6. doi: 10.1001/jama.2024.23410.
    PubMed         Abstract available
    
    
53. POWE CE
    For Gestational Diabetes Pharmacotherapy, Insulin Reigns Supreme.
    JAMA. 2025 Jan 6. doi: 10.1001/jama.2024.27148.
    PubMed        
    
    

    
    Med Care

54. REDDY S, Booth G, Coker-Schwimmer M, Kugley S, et al
    Audio-Based Care for Managing Diabetes in Adults: A Systematic Review.
    Med Care. 2025;63:152-163.
    PubMed         Abstract available
    
    

    
    Metabolism

55. KOKKORAKIS M, Folkertsma P, Forte JC, Wolffenbuttel BHR, et al
    GDF-15 improves the predictive capacity of steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignancies.
    Metabolism. 2025;163:156047.
    PubMed         Abstract available
    
    
56. MEZZA T, Wewer Albrechtsen NJ, Di Giuseppe G, Ferraro PM, et al
    Human subjects with impaired beta-cell function and glucose tolerance have higher levels of intra-islet intact GLP-1.
    Metabolism. 2025;163:156087.
    PubMed         Abstract available
    
    

    
    PLoS One

57. ZHANG Z, Lian Y, He Y, Liu H, et al
    Genetic insights into the risk of hip osteoarthritis on stroke: A single-variable and multivariable Mendelian randomization.
    PLoS One. 2025;20:e0313032.
    PubMed         Abstract available
    
    
58. SHENG C, Xiong Y, Yang P, Wang W, et al
    Moderate-to-vigorous physical activity does not improve mortality in type 2 diabetes patients with severe abdominal aortic calcification.
    PLoS One. 2025;20:e0317007.
    PubMed         Abstract available
    
    
59. KUANG Y, Cheng Z, Zhang J, Yang C, et al
    Risk factors and predictive model construction for lower extremity arterial disease in diabetic patients.
    PLoS One. 2024;19:e0314862.
    PubMed         Abstract available
    
    
60. SAJID M, Malik KR, Khan AH, Iqbal S, et al
    Next-generation diabetes diagnosis and personalized diet-activity management: A hybrid ensemble paradigm.
    PLoS One. 2025;20:e0307718.
    PubMed         Abstract available
    
    
61. 
    Correction: Lifestyle behaviours and associated factors among people with type 2 diabetes attending a diabetes clinic in Ningbo, China: A cross-sectional study.
    PLoS One. 2024;19:e0316772.
    PubMed         Abstract available
    
    
62. JANE LING MY, Ahmad N, Mohd Radi MF, Aizuddin AN, et al
    Development and validation of a Malay version questionnaire for assessing risk perception of type 2 diabetes (RPDM).
    PLoS One. 2025;20:e0311834.
    PubMed         Abstract available
    
    
63. XIE H, Li M, Chen Z, Zheng Y, et al
    Association of metformin use with risk and survival outcome of esophageal cancer in patients with diabetes: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0310687.
    PubMed         Abstract available
    
    
64. TAI YT, Khoo JK, Lim QH, Lim LL, et al
    Are the 2009 Institute of Medicine gestational weight gain recommendations applicable in a contemporary South-East Asian pregnancy cohort? Results of a prospective analysis.
    PLoS One. 2025;20:e0316837.
    PubMed         Abstract available
    
    
65. BAO L, Gong Y, Xu W, Dao J, et al
    Chlorogenic acid inhibits NLRP3 inflammasome activation through Nrf2 activation in diabetic nephropathy.
    PLoS One. 2025;20:e0316615.
    PubMed         Abstract available
    
    

    
    Retina

66. MEDURI A, De Luca L, Oliverio GW, Mancini M, et al
    Dexamethasone Intravitreal Injection in Diabetic Patients Undergoing Cataract Surgery: an updated literature review.
    Retina. 2025 Jan 3. doi: 10.1097/IAE.0000000000004381.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.